Center for Research in Security Prices, LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Photodynamic Therapy Mediated by Topical Application of 5- ALA for the Treatment of Actinic Keratoses

Not Applicable

Withdrawn

Conditions: Actinic Keratosis

Interventions: Drug: 5-ALA plus Blu-Light
Drug: 5-FU, Imiquimod or treatment with cryotherapy

First Posted Date: 2008-12-25

Last Posted Date: 2018-09-10

Lead Sponsor: University of Chicago

Registration Number: NCT00814528

Locations: 🇺🇸
The University of Chicago, Chicago, Illinois, United States

Topical 5-ALA-PDT With Blu-U Therapy Versus Topical 5-ALA With Pulse Dye Laser In Treating Recalcitrant Acne Vulgaris

Not Applicable

Withdrawn

Conditions: Acne Vulgaris

Interventions: Drug: 5-ALA with Candela V-beam Pulse Dye Laser
Drug: 5-ALA with Blu-U Light

First Posted Date: 2008-12-25

Last Posted Date: 2014-12-04

Lead Sponsor: University of Chicago

Registration Number: NCT00814918

Locations: 🇺🇸
The University of Chicago, Chicago, Illinois, United States

A Pilot Investigation of Ciclesonide When Administered as a Hypotonic Versus an Isotonic Formulation of Ciclesonide Nasal Spray

Phase 4

Withdrawn

Conditions: Allergic Rhinitis

Interventions: Drug: placebo, isotonic ciclesonide, hypotonic ciclesonide

First Posted Date: 2008-11-19

Last Posted Date: 2013-06-07

Lead Sponsor: University of Chicago

Registration Number: NCT00793858

Locations: 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States

Effect of Veramyst on the Nasal and Ocular Symptoms of the Early Reaction to Nasal Challenge With Allergen

Phase 4

Completed

Conditions: Allergic Rhinitis

Interventions: Drug: fluticasone furoate
Drug: Placebo

First Posted Date: 2008-11-17

Last Posted Date: 2014-07-08

Lead Sponsor: University of Chicago

Target Recruit Count: 15

Registration Number: NCT00791973

Locations: 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States

Topical ASP-1001 (Contrast Media Formulation) and the Acute Response to Nasal Allergen Challenge (NAC)

Phase 2

Completed

Conditions: Allergic Rhinitis

Interventions: Drug: ASP-1001 nasal spray
Drug: Placebo for ASP-1001

First Posted Date: 2008-11-14

Last Posted Date: 2013-07-10

Lead Sponsor: University of Chicago

Target Recruit Count: 20

Registration Number: NCT00791102

Locations: 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States

The Efficacy of SinoFresh Nasal and Sinus Care Nasal Spray in Eliminating MRSA From the Nasal Cavity

Not Applicable

Withdrawn

Conditions: MRSA Infection

Interventions: Drug: Sinofresh
Drug: Placebo

First Posted Date: 2008-11-14

Last Posted Date: 2016-05-20

Lead Sponsor: University of Chicago

Registration Number: NCT00790972

Locations: 🇺🇸
The University of Chicago, Chicago, Illinois, United States

Immunogenicity and Safety of HPV Vaccine Gardasil in Young Women

Not Applicable

Completed

Conditions: Systemic Lupus Erythematosus

Interventions: Biological: Gardasil

First Posted Date: 2008-11-06

Last Posted Date: 2018-02-15

Lead Sponsor: University of Chicago

Target Recruit Count: 27

Registration Number: NCT00786409

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

MRSA Colonization and Control in the Dallas County Jail

Not Applicable

Completed

Conditions: Methicillin-resistant Staphylococcus Aureus
Skin Diseases, Infectious
Soft Tissue Infections

Interventions: Other: Chlorhexidine
Other: Water

First Posted Date: 2008-11-05

Last Posted Date: 2013-06-12

Lead Sponsor: University of Chicago

Target Recruit Count: 4194

Registration Number: NCT00785200

Locations: 🇺🇸
The Dallas County Jail, Dallas, Texas, United States

Naltrexone in the Treatment of Trichotillomania

Phase 2

Completed

Conditions: Trichotillomania

Interventions: Drug: Placebo
Drug: Naltrexone

First Posted Date: 2008-10-20

Last Posted Date: 2023-02-23

Lead Sponsor: University of Chicago

Target Recruit Count: 51

Registration Number: NCT00775229

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

High-dose Cytarabine/Mitoxantrone Followed by Autotransplantation for t-MDS/t-AML

Phase 2

Completed

Conditions: Acute Myeloid Leukemia
Myelodysplastic Syndrome

Interventions: Drug: Ara-C
Drug: Mitoxantrone
Drug: Etoposide

First Posted Date: 2008-10-16

Last Posted Date: 2014-02-11

Lead Sponsor: University of Chicago

Target Recruit Count: 32

Registration Number: NCT00774046

Locations: 🇺🇸
The University of Chicago, Chicago, Illinois, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy